

# Topical Collection

## Exclusive Papers of the Editorial Board Members (EBMs) of Hemato

### Message from the Collection Editors

This Special Issue of *Hemato* is dedicated to recent advances in hematology, hematopathology, cellular biology, immunology, and molecular biology research areas and comprises a diverse selection of exclusive papers of the Editorial Board Members (EBMs) of *Hemato*. It focuses on highlighting recent interesting investigations conducted in the laboratories or clinics of our journal's EBMs and represents our journal as an attractive open-access publishing platform for hematology-related research data.

---

### Collection Editors

Prof. Dr. Antonino Carbone

Professor of Pathology, Former Chairman of Department of Pathology, Centro di Riferimento Oncologico (CRO) Aviano, National Cancer Institute, Aviano, Italy

Dr. Laurent Garderet

Service d'Hématologie, Hôpital Pitié Salpêtrière, 47/83 boulevard de l'hôpital, F-75013 Paris, France

---



# Hemato

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.0  
CiteScore 2.0



[mdpi.com/si/60803](https://mdpi.com/si/60803)

*Hemato*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[hemato@mdpi.com](mailto:hemato@mdpi.com)

[mdpi.com/journal/  
hemato](https://mdpi.com/journal/hemato)





# Hemato

---

an Open Access Journal  
by MDPI

---

Impact Factor 1.0  
CiteScore 2.0



[mdpi.com/journal/  
hemato](https://mdpi.com/journal/hemato)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Antonino Carbone

Professor of Pathology, Former Chairman of Department of Pathology,  
Centro di Riferimento Oncologico (CRO) Aviano, National Cancer  
Institute, Aviano, Italy

---

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid  
by authors or their institutions.

##### High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,  
and other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 30.6 days after  
submission; acceptance to publication is undertaken in 3.8  
days (median values for papers published in this journal in  
the second half of 2024).